Your session is about to expire
← Back to Search
Beta-lactam/beta-lactamase inhibitor combination antibiotic
Imipenem/Cilastatin/Relebactam for Cystic Fibrosis
Phase 4
Recruiting
Led By Joseph L. Kuti, PharmD
Research Sponsored by Hartford Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights
Summary
This trial tests a combination of three medications given through a drip to treat difficult lung infections in adolescents and adults with Cystic Fibrosis. The treatment aims to help those who don't respond well to regular medications by using drugs that work together to kill tough bacteria.
Who is the study for?
Adults and adolescents with Cystic Fibrosis who are hospitalized for acute pulmonary exacerbations suspected to be caused by P. aeruginosa can join this trial. They must have a confirmed diagnosis of CF, be able to perform lung function tests, and not have severe kidney or liver issues. Pregnant or breastfeeding women and those with certain infections or using specific medications cannot participate.
What is being tested?
The study is testing the antibiotic combination Imipenem/Cilastatin/Relebactam in patients with CF during an acute lung infection. It aims to understand how the body processes the drug, its safety, and if it improves breathing outcomes after treatment.
What are the potential side effects?
Possible side effects may include allergic reactions similar to other antibiotics like rashes, gastrointestinal issues such as nausea or diarrhea, changes in blood test results indicating liver or kidney function alterations, and potential interactions with other drugs.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Imipenem
Imipenem Volume of Distribution
Relebactam Clearance
+1 moreSecondary outcome measures
Probability of Target Attainment at 2 mg/L
Other outcome measures
Pulmonary Function
Side effects data
From 2023 Phase 2 trial • 100 Patients • NCT0498390127%
Febrile Neutropenia
16%
Lung Infection
16%
Sepsis
4%
Fever
4%
Catheter related bloodstream infection
4%
Vomiting
2%
Hematuria
2%
Urinary Tract Infection
2%
Nervous system disorders - Other: Ring-enhancing brain lesions
2%
Peripheral Sensory Neuropathy
2%
Soft Tissue Infection - Cellulitis
2%
Immune system disorders - Other: ICANS
2%
Bacteremia
2%
Infusion related reaction
2%
Hypokalemia
2%
Rash Maculo-papular
2%
Diarrhea
2%
Aspartate Aminotransferase Increased
2%
Jejunal perforation
2%
Allergic Reaction
2%
Appendicitis
2%
Fall
2%
Arterial thromboembolism
2%
Edema limbs
2%
Fungemia
2%
Hyperglycemia
2%
Intracranial Hemorrhage
2%
Confusion
2%
Respiratory failure
2%
Skin and subcutaneous tissue disorders - Other red rash
2%
Heart Failure
2%
Colonic Obstruction
2%
Atrial fibrillation
2%
Ascites
2%
Anorectal Infection
2%
Sinusitis
2%
skin infection
2%
Soft Tissue Infection
2%
Genital edema
2%
Pleural effusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Imipenem-Relebactam Arm
Group II (Cefepime, Meropenem, Piperacillin/Tazobactam)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Imipenem/cilastatin/relebactamExperimental Treatment1 Intervention
Adult participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with the current prescribing information and according to estimated renal function. Adolescent participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with Phase I data \[37.5 (15/15/7.5) mg/kg, up to a maximum dose of 1.25g\]. Each dose will be infused over 30 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imipenem/Cilastatin/Relebactam
2021
Completed Phase 2
~100
Find a Location
Who is running the clinical trial?
St. Christopher's Hospital for ChildrenOTHER
9 Previous Clinical Trials
3,285 Total Patients Enrolled
1 Trials studying Cystic Fibrosis
21 Patients Enrolled for Cystic Fibrosis
Connecticut Children's Medical CenterOTHER
73 Previous Clinical Trials
26,608 Total Patients Enrolled
University of Texas Southwestern Medical CenterOTHER
1,072 Previous Clinical Trials
1,056,246 Total Patients Enrolled
10 Trials studying Cystic Fibrosis
389 Patients Enrolled for Cystic Fibrosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are currently using or planning to use any antibiotics that are inhaled.You have taken or plan to take imipenem or valproic acid within 7 days before receiving the study drug.You have a disease that is rapidly getting worse or a life-threatening illness that is expected to cause death within the next 48 hours, according to the doctor's opinion.You cannot receive any other intravenous antibiotic therapy, except aminoglycosides or fluoroquinolones. However, if you are taking azithromycin as a long-term treatment to reduce flare-ups, that is allowed. It is common to use a combination of antibiotics to treat certain infections in people with CF. This will not affect our main goal, but we will consider it when assessing our secondary goal.You have had a serious allergic reaction to certain antibiotics called β-lactam agents in the past, but a mild rash doesn't count.
Research Study Groups:
This trial has the following groups:- Group 1: Imipenem/cilastatin/relebactam
Awards:
This trial has 3 awards, including:- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger